Skip to main content

Table 3 Patient reported outcome measures

From: The effect of infliximab in patients with chronic low back pain and Modic changes (the BackToBasic study): study protocol of a randomized, double blind, placebo-controlled, multicenter trial

Outcome measures

Timeline

– Oswestry Disability Index (ODI) 2.0, range 0–100 (Primary outcome)

Day 0, 28, 56, 91, 120, 154(5 months) and 278 (9 months)

– Low back pain intensity (mean of three Numeric Rating Scales (NRSs, range 0–10); current LBP, the worst LBP within the last 2 weeks, and usual/mean LBP within the last 2 weeks (for weekly reports during the intervention period; the wording “last 2 weeks” will be replaced by “the last week”)

Every week during treatment period and at day 154(5 months) and 278 (9 months)

– Roland and Morris Disability Questionnaire (RMDQ), range 0–24

Day 0, 56, 154(5 months) and 278 (9 months)

– Leg pain intensity (NRSs, range 0–10) last week

Day 0, 56, 154(5 months) and 278 (9 months)

– Hours with LBP during the last 4 weeks

Day 0, 56, 154(5 months) and 278 (9 months)

– Symptom-specific well-being

Day 0, 56, 154(5 months) and 278 (9 months)

– Days with sick leave

Day 0, 28, 56, 91, 120, 154(5 months) and 278 (9 months)

– Co-interventions

Day 0, 28, 56, 91, 120, 154(5 months) and 278 (9 months)

– Concomitant medication

Day 0, 28, 56, 91, 120, 154(5 months) and 278 (9 months)

– Patients’ satisfaction

Day 0, 56, 154(5 months) and 278 (9 months)

– Global perceived effect

Day 0, 56, 154(5 months) and 278 (9 months)

– EQ. 5D-5L

Day 0, 56, 154(5 months) and 278 (9 months)

– Emotional distress (Hopkins Symptom Checklist–25)

Reported at baseline

– Fear-avoidance beliefs Questionnaire (FABQ)

Reported at baseline

– Subjective health complaints (SHC)

Reported at baseline

– Background information

Reported at baseline

– Perceived treatment

Day 7, 56, 154(5 months) and 278 (9 months)